Soluble Guanylate Cyclase Stimulators in Heart Failure

Nida Mirza ^[2] | Dr. M. Vijaya Bhargavi ^[2]

Abstract: Heart failure nowadays has a high degree of morbidity and mortality rates. Various treatments have been introduced but still the prognosis remains poor. This justifies the search of newer agents with the development of soluble cyclase guanylate inhibitors which has been studied through the NO oxide pathway cyclase. Therefore, the development of the sGCs have reduced the risk of hospitalizations with heart failure with reduced ejection fraction that are at a high risk of cardiovascular events. The novel sGC stimulators increase sGC sensitivity to NO and independently stimulate sGC, whereas the sGC activators target oxidized and heme free sGC to stimulate cGMP production. This review will discuss the pathophysiologic basis for sGC stimulator and activator use in HFrEF, review pre-clinical and clinical data, and propose a place in the HFrEF armamentarium for this novel pharmacotherapeutic class

Keywords: sGCs, cGMP, Heart Failure, HFpEF,HFrEF, PAH, CTEPH

Edition: Volume 12 Issue 12, December 2023,

Pages: 259 - 264